Estrella Immunopharma (ESLA) Shares Outstanding (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Shares Outstanding (Entity) of $43.2 million for Q1 2026, up 1849.46% year-over-year from $2.2 million in Q1 2025, and up 12.2% quarter-over-quarter from $38.5 million in Q4 2025.
Estrella Immunopharma (ESLA) Shares Outstanding (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Shares Outstanding (Entity) for 6 consecutive years, with $43.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1849.46% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $43.2 million (up 1849.46% YoY), while the FY2025 annual figure was $38.5 million, up 1637.53% from the prior year.
- Shares Outstanding (Entity) rose to $43.2 million in Q1 2026 per ESLA's latest filing, from $38.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $43.2 million in Q1 2026 and bottomed at $168758.0 in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $16.4 million across 5 years, with a median of $2.2 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) surged 20759.0% — and 2025, when it plunged 93.95%.
- Estrella Immunopharma's Shares Outstanding (Entity) stood at $168758.0 in 2022, then soared by 20759.0% to $35.2 million in 2023, then slumped by 93.71% to $2.2 million in 2024, then jumped by 1637.53% to $38.5 million in 2025, then increased by 12.2% to $43.2 million in 2026.
- Business Quant data shows ESLA's Shares Outstanding (Entity) at $43.2 million in Q1 2026, $38.5 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 43.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.00 Mn |
| Mar 31, 2026 | 42.12 Mn |
| Dec 31, 2025 | 36.82 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 36.17 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 36.21 Mn |
| Jun 30, 2024 | 36.38 Mn |
| Mar 31, 2024 | 35.52 Mn |
| Dec 31, 2023 | 35.20 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 168,758.00 |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.42 Mn |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 1.28 Mn |